Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
J Gastrointest Surg ; 25(1): 67-76, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-33140322

RESUMEN

INTRODUCTION: After endoscopic resection (ER) of neoplasia in Barrett's esophagus (BE), it is recommended to ablate the remaining BE to minimize the risk for metachronous disease. However, we report long-term outcomes for a nationwide cohort of all patients who did not undergo ablation of the remaining BE after ER for early BE neoplasia, due to clinical reasons or performance status. METHODS: Endoscopic therapy for BE neoplasia in the Netherlands is centralized in 8 expert centers with specifically trained endoscopists and pathologists. Uniformity is ensured by a joint protocol and regular group meetings. We report all patients who underwent ER for a neoplastic lesion between 2008 and 2018, without further ablation therapy. Outcomes include progression during endoscopic FU and all-cause mortality. RESULTS: Ninety-four patients were included with mean age 74 (± 10) years. ER was performed for low-grade dysplasia (LGD) (10%), high-grade dysplasia (HGD) (25%), or low-risk esophageal adenocarcinoma (EAC) (65%). No additional ablation was performed for several reasons; in 73 patients (78%), the main argument was expected limited life expectancy. Median C2M5 BE persisted after ER, and during median 21 months (IQR 11-51) with 4 endoscopies per patient, no patient progressed to advanced cancer. Seventeen patients (18%) developed HGD/EAC: all were curatively treated endoscopically. In total, 29/73 patients (40%) with expected limited life expectancy died due to unrelated causes during FU, none of EAC. CONCLUSION: In selected patients, ER monotherapy with endoscopic surveillance of the residual BE is a valid alternative to eradication therapy with ablation.


Asunto(s)
Adenocarcinoma , Esófago de Barrett , Ablación por Catéter , Neoplasias Esofágicas , Lesiones Precancerosas , Adenocarcinoma/cirugía , Anciano , Esófago de Barrett/cirugía , Neoplasias Esofágicas/cirugía , Esofagoscopía , Humanos , Países Bajos/epidemiología , Lesiones Precancerosas/cirugía
2.
Crit Rev Oncol Hematol ; 92(1): 25-37, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-24935219

RESUMEN

Barrett's metaplasia of the esophagus (BE) is the precursor lesion of esophageal adenocarcinoma (EAC), a deadly disease with a 5-year overall survival of less than 20%. The molecular mechanisms of BE development and its transformation to EAC are poorly understood and current surveillance and treatment strategies are of limited efficacy. Increasing evidence suggests that aberrant signaling through pathways active in the embryological development of the esophagus contributes to BE development and progression to EAC. We discuss the role that the Bone morphogenetic protein, Hedgehog, Wingless-Type MMTV Integration Site Family (WNT) and Retinoic acid signaling pathways play during embryological development of the esophagus and their contribution to BE development and malignant transformation. Modulation of these pathways provides new therapeutic opportunities. By integrating findings in developmental biology with those from translational research and clinical trials, this review provides a platform for future studies aimed at improving current management of BE and EAC.


Asunto(s)
Esófago de Barrett/etiología , Esófago de Barrett/patología , Transformación Celular Neoplásica , Transducción de Señal , Adenocarcinoma/etiología , Adenocarcinoma/terapia , Animales , Esófago de Barrett/terapia , Progresión de la Enfermedad , Neoplasias Esofágicas/etiología , Neoplasias Esofágicas/terapia , Humanos , Terapia Molecular Dirigida
3.
Neth J Med ; 71(7): 355-8, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24167833

RESUMEN

INTRODUCTION: Recurrent bleeding from an upper gastrointestinal ulcer when endoscopy fails is a reason for radiological or surgical treatment, both of which have their advantages and disadvantages. CASE: Based on a patient with recurrent gastrointestinal bleeding, we reviewed the available evidence regarding the efficacy and safety of surgical treatment and embolisation, respectively. DISCUSSION: Transarterial embolisation (TAE) and surgical treatment are both options for recurrent gastrointestinal bleeding when endoscopy fails. Both therapies have serious complications and a risk of rebleeding. Choosing the therapy depends on the capability of the patient to tolerate haemodynamic instability, resuscitation and hypotension. CONCLUSION: Choosing between TAE and surgery depends a great deal on the case presented, haemodynamic stability and the skills and tools available at that moment.


Asunto(s)
Úlcera Duodenal/complicaciones , Embolización Terapéutica , Úlcera Péptica Hemorrágica/etiología , Úlcera Péptica Hemorrágica/terapia , Hemostasis Endoscópica , Humanos , Masculino , Persona de Mediana Edad , Úlcera Péptica Hemorrágica/cirugía , Recurrencia
4.
Endoscopy ; 44(1): 4-12, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22109651

RESUMEN

BACKGROUND AND STUDY AIMS: Endoscopic resection is the cornerstone of endoscopic treatment of esophageal high grade dysplasia or early cancer. Endoscopic resection is, however, a technically demanding procedure, which requires training and expertise. The aim of the current study was to prospectively evaluate efficacy and safety of the first 120 endoscopic resection procedures of early esophageal neoplasia performed by six endoscopists (20 endoscopic resections each) who were participating in an endoscopic resection training program. PATIENTS AND METHODS: The program consisted of four tri-monthly 1-day courses with lectures, live-demonstrations, hands-on training on anesthetized pigs, and one-on-one hands-on training days. Gastroenterologists from centers with multidisciplinary expertise in upper gastrointestinal oncology participated, together with an endoscopy nurse and a pathologist. Outcome measures were complete endoscopic removal of the target area and acute complications. RESULTS: A total of 120 consecutive esophageal endoscopic resection procedures (85 ER-cap, 35 multiband mucosectomy [MBM]) were performed by six endoscopists: 109 in Barrett's esophagus, 11 for squamous neoplasia; 85 piecemeal endoscopic resections (median 3 specimens, interquartile range 2 - 4 specimens). Complete endoscopic removal was achieved in 111 /120 cases (92.5 %). Six perforations occurred (5.0 %): five were effectively treated endoscopically (clips, covered stent), and one patient underwent esophagectomy. There were 11 acute mild bleedings (9.2 %), which were managed endoscopically. Perforations occurred in ER-cap procedures performed by four participants (7.1 % ER-cap vs. 0 % MBM; P = 0.18), and in 1.7 % of the first 10 endoscopic resections and 8.3 % of the second 10 endoscopic resections per endoscopist (P = 0.26). CONCLUSION: In this intense, structured training program, the first 120 esophageal endoscopic resections performed by six participants were associated with a 5.0 % perforation rate. Although perforations were adequately managed, performing 20 endoscopic resections may not be sufficient to reach the peak of the learning curve in endoscopic resection.


Asunto(s)
Carcinoma de Células Escamosas/cirugía , Educación de Postgrado en Medicina , Neoplasias Esofágicas/cirugía , Esofagoscopía/educación , Esófago/cirugía , Hemorragia Gastrointestinal/etiología , Anciano , Animales , Esófago de Barrett/patología , Esófago de Barrett/cirugía , Carcinoma de Células Escamosas/patología , Competencia Clínica , Neoplasias Esofágicas/patología , Perforación del Esófago/etiología , Perforación del Esófago/terapia , Esofagoscopía/efectos adversos , Femenino , Hemorragia Gastrointestinal/terapia , Humanos , Curva de Aprendizaje , Masculino , Persona de Mediana Edad , Membrana Mucosa/cirugía , Porcinos , Resultado del Tratamiento
5.
Endoscopy ; 41(10): 913-6, 2009 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19750453

RESUMEN

Endoscopes, including duodenoscopes, are medical devices that are frequently associated with outbreaks of nosocomial infections. We investigated an outbreak of multidrug-resistant PSEUDOMONAS AERUGINOSA sepsis affecting three patients after endoscopic retrograde cholangiopancreaticography (ERCP). Epidemiologic investigation supplemented by molecular typing revealed that one ERCP scope was the source of infection with P. AERUGINOSA. No contamination with this microorganism was found after screening of washer-disinfectors, connecting tubes, and environmental surfaces in the endoscopy center. PSEUDOMONAS isolates from blood and endoscope channels before gas sterilization with ethylene oxide (ETO) were characterized by molecular typing as "linked isolates". Though the current surveillance system did not prevent the infections in three patients, our microbiological surveillance protocol with routine culturing of endoscopes was helpful in detecting the source of contamination and probably avoided numerous cross-contaminations in other patients who underwent ERCP procedures with endoscopes.


Asunto(s)
Infección Hospitalaria/microbiología , Brotes de Enfermedades/prevención & control , Duodenoscopios/microbiología , Infecciones por Pseudomonas/prevención & control , Sepsis/microbiología , Anciano , Farmacorresistencia Bacteriana Múltiple , Femenino , Humanos , Masculino , Persona de Mediana Edad , Infecciones por Pseudomonas/etiología , Pseudomonas aeruginosa/aislamiento & purificación
6.
Ned Tijdschr Geneeskd ; 151(34): 1879-84, 2007 Aug 25.
Artículo en Holandés | MEDLINE | ID: mdl-17902562

RESUMEN

OBJECTIVE: To gain more insight into current surveillance and treatment of patients with Barrett's oesophagus with the aim of developing new guidelines. DESIGN: Questionnaire. METHOD: In 2004, a questionnaire was sent to 337 physician-endoscopists who were all registered with the Netherlands Society of Gastroenterology. The questionnaire inventoried various aspects of surveillance and treatment of patients with Barrett's oesophagus. RESULTS: Of the 289 respondents (86%), 96% carried out surveillance or had it carried out, on at least a proportion of their patients with Barrett's oesophagus. A total of 258 respondents (89%) carried out the surveillance themselves. An endoscopic indication of the presence of Barrett's oesophagus was, for 31% of the respondents, enough reason to carry out surveillance of this condition irrespective of the results of pathological investigations. 75% applied an age limit for surveillance for Barrett's. The median age limit is 75 years (interquartile distance: 70-75) and 46% of the treating professionals limited themselves to patients who, on the basis of age and co-morbidity, may undergo oesophageal resection. The choice of treatment in early neoplasia, surgical or endoscopic, depends not only on the histological diagnosis, but also on the age and the co-morbidities of the patient. CONCLUSION: Surveillance of Barrett's oesophagus is widespread in the Netherlands, and in general is carried out in accordance with international guidelines. The possibilities of treating patients with high-grade dysplasia or intramucosal carcinoma of the oesophagus endoscopically, and of consulting external advisory bodies are still insufficiently utilized.


Asunto(s)
Esófago de Barrett/epidemiología , Esófago de Barrett/terapia , Esofagoscopía/métodos , Guías de Práctica Clínica como Asunto , Pautas de la Práctica en Medicina , Factores de Edad , Anciano , Humanos , Países Bajos/epidemiología , Encuestas y Cuestionarios
7.
Int J Tuberc Lung Dis ; 11(1): 85-90, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17217135

RESUMEN

OBJECTIVES: Percutaneous endoscopic gastrostomy (PEG) is a widely used method for providing long-term administration of tube feeding. Different indications in relation to diseases, impairments and nutritional factors for PEG placement have been mentioned in guidelines. Treatment with PEG has not been described previously for tuberculosis (TB). Our aim was to identify and describe indications and contributing factors for PEG placement in TB patients. METHODS: A retrospective medical record review was conducted of 32 TB patients who required PEG from March 1996 to April 2004. Indications and contributing factors for PEG placement were analysed. RESULTS: PEG placement was based on three different indications. In 18 patients, PEG was used to administer tube feeding, in 4 patients anti-tuberculosis drugs were administered and in 10 patients both tube feeding and antituberculosis drugs were administered. Contributing factors for PEG placement were swallowing disabilities, weakness, anti-tuberculosis drugs and their side effects, pain of neuralgic origin, hiccups and refusal of food and drugs. CONCLUSIONS: In TB, imminent and overt malnutrition, as well as the administration of drugs with a curative aim, are new indications for PEG placement. The use of PEG can overcome various problems in TB treatment and prevent treatment default.


Asunto(s)
Nutrición Enteral/métodos , Gastroscopía , Gastrostomía , Tuberculosis/dietoterapia , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Resultado del Tratamiento , Tuberculosis/complicaciones
8.
Ned Tijdschr Geneeskd ; 150(19): 1059-64, 2006 May 13.
Artículo en Holandés | MEDLINE | ID: mdl-16733981

RESUMEN

Gastro-oesophageal reflux disease is a chronic disorder. The most important therapeutic measure is long-term pharmacological acid inhibition. Anti-reflux surgery plays a role in cases where pharmacological treatment fails. A new development is endoluminal treatment for reflux disorders. The various methods used are based on one of the following principles: radiofrequency ablation, gastroplication and implantation of a bulking agent. Short-term results with endoluminal treatment are not very positive and longer-term results have been disappointing so far. Results from randomised studies are still largely unavailable. Longer follow-up and controlled randomised studies are needed before a well-founded judgment can be made regarding the place of endoluminal treatment in the therapeutic armamentarium.


Asunto(s)
Antiácidos/uso terapéutico , Endoscopía del Sistema Digestivo/métodos , Reflujo Gastroesofágico/tratamiento farmacológico , Reflujo Gastroesofágico/cirugía , Ensayos Clínicos como Asunto , Terapia Combinada , Humanos , Resultado del Tratamiento
10.
Aliment Pharmacol Ther ; 20(8): 843-50, 2004 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-15479355

RESUMEN

BACKGROUND: Azathioprine is widely used in Crohn's disease. A major drawback is the occurrence of side-effects, especially acute pancreatitis. Acute pancreatitis is rarely seen when azathioprine is used for other diseases than Crohn's disease. AIM: To survey side-effects of azathioprine after liver or renal transplantation, for systemic lupus erythematosis, Wegener's granulomatosis, autoimmune hepatitis, rheumatoid arthritis, ulcerative colitis or Crohn's disease. METHODS: A computerized search using the term 'azathioprine' or 'imuran' was performed on the Hospital Information System of the university hospital Groningen, resulting in 1564 patients matching our criteria. RESULTS: Eleven of 224 patients with Crohn's disease experienced acute pancreatitis (4.9%) compared with two of 129 (1.5%) with autoimmune hepatitis, two of 388 (0.5%) after renal transplantation, one of 254 (0.4%) after liver transplantation. Acute pancreatitis was more prevalent in Crohn's disease compared with any other disease. Azathioprine-toxicity necessitating withdrawal occurred significantly (P < 0,05) more in rheumatoid arthritis (78 of 317), ulcerative colitis (20 of 94) and Crohn's disease (52 of 224) compared with systemic lupus erythematosis (five of 73), Wegener's granulomatosis (six of 85), autoimmune hepatitis (eight of 129), after liver transplantation (17 of 254) and after renal transplantation (22 of 388). CONCLUSIONS: Acute pancreatitis is strongly associated with Crohn's disease and rarely occurs with other underlying conditions. Overall azathioprine-induced toxicity and the necessity of withdrawal is more common in inflammatory bowel disease and rheumatoid arthritis compared with other diseases.


Asunto(s)
Antimetabolitos/efectos adversos , Azatioprina/efectos adversos , Enfermedad de Crohn/tratamiento farmacológico , Pancreatitis/inducido químicamente , Enfermedad Aguda , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos
11.
Ned Tijdschr Geneeskd ; 147(13): 616-9, 2003 Mar 29.
Artículo en Holandés | MEDLINE | ID: mdl-12701397

RESUMEN

In two patients, women aged 73 and 46 years, gastrointestinal symptoms were initially not recognised as a paraneoplastic syndrome due to small-cell lung cancer. This led to redundant diagnostics as well as a delay in final diagnosis. The anti-Hu syndrome is characterised by the presence of anti-Hu antibodies and neurological symptoms. About a quarter of the patients with the anti-Hu syndrome will develop gastrointestinal motility disorders in the course of their illness. The primary tumour is usually a small-cell lung cancer. Whereas the presence of anti-Hu antibodies appears to be beneficial for the oncological prognosis, the neurological outcome is less favourable.


Asunto(s)
Autoanticuerpos/análisis , Carcinoma de Células Pequeñas/inmunología , Neoplasias Pulmonares/inmunología , Proteínas del Tejido Nervioso/inmunología , Síndromes Paraneoplásicos/inmunología , Proteínas de Unión al ARN/inmunología , Anciano , Carcinoma de Células Pequeñas/diagnóstico , Diagnóstico Diferencial , Proteínas ELAV , Femenino , Enfermedades Gastrointestinales/diagnóstico , Motilidad Gastrointestinal , Humanos , Neoplasias Pulmonares/diagnóstico , Persona de Mediana Edad , Enfermedades del Sistema Nervioso/diagnóstico , Síndromes Paraneoplásicos/diagnóstico , Pronóstico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA